Pfizer Inc. (NYSE:PFE) Shares Purchased by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 25.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,075,245 shares of the biopharmaceutical company’s stock after buying an additional 419,502 shares during the quarter. Pfizer comprises approximately 1.4% of Letko Brosseau & Associates Inc.’s portfolio, making the stock its 25th largest position. Letko Brosseau & Associates Inc.’s holdings in Pfizer were worth $76,120,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. 25 LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $25,000. Worth Asset Management LLC purchased a new position in Pfizer during the first quarter worth about $29,000. Steward Financial Group LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $43,000. GeoWealth Management LLC acquired a new position in shares of Pfizer in the 1st quarter worth approximately $49,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new stake in Pfizer in the 4th quarter valued at approximately $50,000. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.1 %

PFE stock traded up $0.04 during trading on Monday, hitting $29.96. 8,418,016 shares of the company’s stock were exchanged, compared to its average volume of 25,466,814. The business has a 50-day moving average price of $31.97 and a two-hundred day moving average price of $35.23. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $169.17 billion, a price-to-earnings ratio of 16.35, a PEG ratio of 1.91 and a beta of 0.63. Pfizer Inc. has a 52-week low of $28.93 and a 52-week high of $54.93.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.15. The business had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $13.77 billion. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. As a group, equities research analysts expect that Pfizer Inc. will post 1.56 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 5.47%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 89.62%.

Analysts Set New Price Targets

A number of research analysts have commented on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price target on shares of Pfizer in a research note on Monday, October 2nd. StockNews.com assumed coverage on Pfizer in a report on Thursday, October 5th. They set a “hold” rating for the company. Jefferies Financial Group raised shares of Pfizer from a “hold” rating to a “buy” rating and increased their price target for the stock from $38.00 to $39.00 in a research report on Monday, October 16th. Citigroup dropped their price objective on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating for the company in a report on Monday, October 16th. Finally, Barclays reduced their target price on shares of Pfizer from $35.00 to $34.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 1st. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $42.50.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.